Nitra's Embedded Lending Advantage

The real significance is that Nitra can turn payment data into underwriting advantage, which gives it a second engine beyond swipe fees. Its card already sits inside clinic purchasing and bill pay, so it can see who vendors are, when invoices hit, and how fast a practice spends. That makes working capital, equipment finance, and short term liquidity products a natural extension of an existing workflow, not a separate loan sale.

• Interchange is valuable but structurally squeezable. Nitra nets roughly 1 percent on card volume after bank, network, and rewards costs, and it already flags interchange compression as a core risk. Credit revenue is different. It is priced off underwriting and capital efficiency, so it does not depend on card rails staying generous.
  1 sacra 2 sacra
• The setup for lending is already there. Nitra raised a $45 million debt facility in August 2022 to support charge card working capital, and in March 2026 expanded warehouse capacity as processing volume passed $1 billion. That kind of capital base is what turns embedded credit from a feature idea into an actual balance sheet business.
  1 sacra 3 nitra
• The closest comparables show both the upside and the requirement. Brex and Ramp proved that card plus workflow software can capture daily finance activity, then use that control point to expand. Brex has also emphasized that scaling credit requires debt warehouses, underwriting, fraud controls, and capital markets infrastructure, not just card issuing APIs.
  1 sacra 4 nitra 5 sacra

The next step is for Nitra to make financing part of the act of buying, approving, and paying, especially for supply purchases and cash flow gaps inside independent practices. If that happens, revenue mix shifts away from pure interchange, margins improve, and the product becomes much harder to replace because clinics would be moving both spend and operating credit through the same system.